Company / Return on Equity (ROE)
AMICUS THERAPEUTICS, INC. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-9.9%
FY2025
5-year range
-192.3% / -9.9%
FY2021-FY2025
Trend
+65.8%
vs FY2024
Sector context
#63 of 190
Health Care
What the data says
AMICUS THERAPEUTICS, INC. reports negative total equity of -9.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-9.9% in FY2025 with a 5-year CAGR of +86.8%.
Improved from -94.6% to -9.9% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +182.4pp
- 5-Year Change
- +86.8pp
- 10-Year Change
- -
Sector benchmark
#63 of 190 in Health CareTop 33% of 190This company -9.9% Sector average -50.3%
▼
+80.3% above sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 65.8% year-over-year.
- Currently 40.4pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -9.9% | +65.8% |
| FY2024 | -28.9% | +69.5% |
| FY2023 | -94.6% | +50.8% |
| FY2022 | -192.3% | -135.9% |
| FY2021 | -81.5% | +15.7% |
| FY2020 | -96.7% | -29.2% |
| FY2019 | -74.8% | +26.5% |
| FY2018 | -101.8% | -26.4% |
| FY2017 | -80.5% | -44.9% |
| FY2016 | -55.5% | -46.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026